Read and report vaccine reactions, harassment and failures.
According to the U.S. Department of Health and Human Services, adverse events are classified into five grades. The guidelines are as follows:
Grade 1 - Considered mild or asymptomatic and no intervention is required.
Grade 2 - A moderate event but minimal, local or noninvasive interventions are indicated. In some situations, certain activities of daily living are limited (shopping, meal preparations, using the telephone).
Grade 3 - Considered a severe or medically significant adverse event but not one that is considered immediately life-threatening. In certain cases, hospitalization, including long-term hospitalization is needed. Grade 3 reactions are disabling and limit a person’s ability to perform activities of daily living (feeding self, bathing, self-care).
Grade 4 - A life-threatening event where urgent intervention is required
Grade 5 - Death related to an adverse event
Under EUA authority, the FDA Commissioner may permit “unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN (CBRN = chemical, biological, radiological, nuclear) threat agents when there are no adequate, approved, and available alternatives.”1
Most COVID-19 vaccines in use in the United States have an EUA status. To learn more about EUA products and vaccines and consumer rights, visit NVIC’s FAQ on Emergency Use Vaccines (EUA) & Vaccine Injury Compensation.
More than 50 percent of adult participants involved in the Phase 1/2 human trials of Pfizer and BioNTech’s experimental messenger RNA (ribonucleic acid) COVID-19 vaccine reported adverse reactions. The trial was conducted in May and June 2020, and involved 45 healthy adults between the ages of 18 and 55 years. Limitations of this data were noted as not accurately reflecting populations at highest risk for COVID-19.2
In the trials, 12 adults received a 10-microgram dose of the BNT162b1 vaccine, 12 adults were injected with a 30-µg dose, 12 received a 100-µg dose, while nine adults were given an inert saline placebo. Within seven days of vaccination, seven (58.3 percent) of the participants in the 10-µg group reported adverse reactions (pain) near the injection site and 24–or 100 percent–in the 30-µg and 100-µg groups and two (22.2 percent) in the placebo group reported reactions. Severe pain was reported by one participant who received 100-µg dose.3 4
Three weeks after the initial vaccination with the Pfizer-BioNTech experimental vaccine, all clinical trial participants were given a second dose of the vaccine at the same dosage. Of the participants in the 10-µg group, 8.3 percent developed fevers. Of those in the 30-µg group, 75 percent developed fevers. More than 50 percent of the adults, who were given either a 10-µg or 30-µg dose, experienced an adverse reaction such as sleep disturbances and fever. Two participants suffered severe reactions. A Grade 3 fever of over 101.3°F two days after vaccination was experienced by one adult in the 30-µg group and sleep disturbance one day after vaccination was experienced by one adult in the 100-µg group.5 6
Pfizer reported early U.S. Phase 3 clinical trials results in mid-September. Company executives presented safety data for 5,664 individuals between 18 and 64 years of age, and 1,816 persons between 65 and 85 years who received one dose. In the younger age category, 16 percent reported chills, 35 percent complained of headache and 38 percent reported fatigue following vaccination. Eleven percent or less suffered diarrhea, joint pain, or chills. Side effects were reportedly lower among persons aged 65 to 85 years.7
After the second vaccine dose, 36 percent of trial participants between the ages of 18 and 64 reported fatigue, while 28 percent reported a headache and 18 percent reported muscle pain. Most adverse effects following the second dose were reported as mild to moderate; however, some participants did experience severe or life-threatening adverse reactions. Severe side effects occurred more frequently after the second dose.8
On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech’s messenger RNA (mRNA) COVID-19 vaccine for use in persons 16 years of age and older.9
According to the Fact Sheet for Healthcare Providers Administering the Pfizer-BioNTech COVID-19 vaccine, the most commonly reported side effects were injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site swelling and redness, nausea, malaise, and swollen lymph nodes.10
Additional adverse events reported in clinical trials included 12 cases of appendicitis (eight in the vaccine group vs. four in the placebo group), 70 cases of lymphadenopathy (64 in the vaccine group vs. 6 in the placebo group), and four cases of Bell’s Palsy, all in the vaccine group.
In the data released at the December 10, 2020 Vaccines and Related Biological Products Advisory Committee meeting, six deaths were reported to have occurred during the clinical trials, two in the vaccine arm and four in the placebo arm. Of the two deaths in the vaccine arm, one person was reported as having a cardiac arrest 62 days post Dose 2 and the other was reported as atherosclerotic disease and died three days after Dose 1.11
Excess Adverse Events in Pfizer-BioNTech Vaccine Clinical Trials
A study published in Vaccine in September 2022 found that participants who received an mRNA COVID-19 were at a higher risk of experiencing a serious adverse reaction. The risk of an adverse reaction was higher than what was initially estimated at the time that the Pfizer-BioNTech mRNA COVID-19 vaccine was granted the EUA. According to the study, there were 10.1 additional events for every 10,000 individuals vaccinated and that 1 in 800 adults who received the Pfizer-BioNTech mRNA COVID-19 vaccine experienced a serious adverse event.12
Study authors also found that the risk of trial participants suffering a vaccine adverse event was greater than the reduction in COVID-19 related hospitalizations.13
On May 10, 2021, the FDA expanded the EUA granted Pfizer/BioNTech to distribute its experimental mRNA vaccine in the U.S. to include administration to children as young as 12 years old14 and the CDC’s ACIP voted to approve its use in this population on May 12, 2021.15
The approval for use in adolescents 12 to 15 years was based on a small clinical trial involving 2,260 teens, of which 1,131 received the vaccine and 1,129 received a saline placebo.16 According to the FDA’s Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine, the most common reported adverse events in adolescents 12 through 15 year olds included injection site pain, fatigue, headache, chills, muscle pain, fever, joint pain, injection site swelling and redness, lymph node swelling, and nausea.17
During the clinical trial, nearly 11 percent of 12- to 15-year-olds experienced a severe or Grade 3 vaccine reaction, with one study participant experiencing a Grade 4 reaction of a fever of 40.4°C. Five adolescents who received the Pfizer vaccine experienced a serious adverse event (SAE) during the trial, however, none of these events were considered by clinical trial investigators to be related to vaccination.18
On June 17, 2022, the FDA authorized use of a 3mcg dose of Pfizer-BioNTech COVID-19 vaccine for use in children six months through four years of age. According to the FDA, in children six through 23 months of age, the most common reported adverse events included fever and pain, redness, swelling and tenderness of the injection site, decreased appetite, and irritability. Similar reactions were noted among children ages two to four years of age, with the additional symptoms of chills, fever, and headache.25
Seventeen children aged six through 23 months of age experienced a serious adverse event (SAE) following receipt of the vaccine in clinical trials. SAEs included pneumonia, RSV bronchiolitis, gastroenteritis, rotavirus gastroenteritis, viral gastroenteritis, accidental overdose, febrile convulsion, seizure, lower respiratory tract infection, anal abcess, metapneumovirus infection, and anaphylaxis. According to the trial investigators, none of the SAEs were considered to be related to the vaccine.26
Twelve children aged two through four years of age were reported to have experience one or more SAEs during the clinical trial. These SAEs included dehydration, appendicitis, pain in the extremities, pyrexia, focal peritonitis, status epilepticus, epilepsy, febrile convulsion, viral gastroenteritis, rotavirus gastroenteritis, gastroenteritis, diarrhea, upper respiratory tract infection and lower respiratory tract infection. Trial investigators considered two SAEs, pyrexia and pain in the extremities, reported in a four-year-old trial participant, to be related to vaccination. This patient required treatment in the emergency department and hospitalization for several days due to persistant fever and moderate calf pain.27
According to data released July 7, 2023 by the CDC, reports received by VAERS for the Pfizer-BioNTech experimental COVID-19 vaccine totaled over 922,150 vaccine adverse events with 204,153 categorized as serious. Noted within these reports were 22,324 deaths; 47,624 permanent disabilities; 137,166 hospitalizations; 91,402 emergency room visits, and 25,685 life threatening events. Also noted in these reports were that 738 deaths reported were categorized as senior living administration, with 91 percent of overall reported deaths occurring in persons 65 years of age and older.
Even though the National Childhood Vaccine Injury Act of 1986 legally required pediatricians and other vaccine providers to report serious health problems following vaccination to VAERS, many doctors and other medical workers giving vaccines to children and adults fail to report vaccine-related health problem to VAERS. There is evidence to suggest that only between 1 and 10 percent of serious health problems that occur after use of prescription drugs or vaccines in the U.S. are ever reported to federal health officials who are responsible for regulating the safety of drugs and vaccines and issue national vaccine policy recommendations.28 29 30 31
Moderna COVID-19 Vaccine Trial Data in Adults
On May 18, 2020, Moderna, Inc. of Cambridge, Massachusetts announced that it had obtained “positive interim clinical data” from a Phase 1 human clinical trial of its experimental mRNA-1273 COVID-19 vaccine. However, four out of 45 healthy clinical trial participants experienced serious (Grade 3) vaccine reactions.32
Each of the 45 participants was given two doses of the Moderna vaccine about a month apart at dosage levels that were either 25, 100 or 250 micrograms (µg). The mRNA-1273 vaccine reportedly produced a “Grade 3 adverse event” in one participant who received doses of between 25 µg and 100 µg. That individual experienced Grade 3 erythema (a rash) around the injection site. A Grade 3 rash can include blistering, open ulcers, wet peeling (moist desquamation) or a serious rash over large areas of the body.33
Three participants in the clinical trial who received a vaccine dose of 250 µg experienced “Grade 3 systemic symptoms” following administration of the second dose. Moderna described these as the “most notable” of the adverse events and said that they had been “transient and self-resolving.” 34
On July 27, 2020, the National Institutes of Health (NIH) announced that Phase 3 trials of Moderna’s mRNA-1273 had begun. According to the press release issued by NIH:35
“Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned 1:1 to receive either two 100 microgram (mcg) injections of mRNA-1273 or two shots of a saline placebo. The trial is blinded, so the investigators and the participants will not know who is assigned to which group.”
In September 2020, three participants involved in the Phase 3 trial reported suffering reactions such as high fever, headaches, body aches andexhaustion. One of these participants, 44-year-old Luke Hutchison of Utah, suffered a bad headache, chills, a fever (over 100°F), and shortness of breath after getting the second vaccine dose. Hutchison described his symptoms as “full-on COVID-like symptoms.” He cautioned that people receiving the vaccine should be made aware that serious adverse reactions can occur, especially after the second dose.36 Another of the trial participants, a woman in her 50s from North Carolina, suffered a migraine that “left her exhausted and struggling to focus.”37
On November 16, 2020, Moderna reported that adverse reactions were generally mild or moderate, and included headache, fatigue, and injection site pain38
The FDA issued an EUA for Moderna’s COVID-19 vaccine on December 18, 2020. In its press release, the FDA reported that during clinical trials, common reactions following Moderna vaccination included injection site pain, headache, fatigue, joint and muscle pain, fever, nausea, vomiting, and swelling of the lymph nodes in the arm where the vaccine was given. Vaccine adverse events typically persisted for several days and were more common following the second dose of the two-dose series.39
Serious adverse events occurring at higher rates in the vaccine group included myocardial infarction, kidney stones, gall bladder inflammation and Bell’s Palsy. Seven serious adverse events occurred in the vaccine group following vaccination, with four considered by clinical trial investigators to be related to the vaccine. These included intractable nausea and vomiting, rheumatoid arthritis, and two incidents of facial swelling that occurred in persons who had previously received cosmetic injections of dermal fillers.40
Thirteen deaths were reported during the clinical trials, with six occurring in the vaccine group and seven in the placebo group. In the vaccine group, two individuals over the age of 75 years with a history of heart disease died of heart related complications, two individuals were found deceased at home and the exact cause was not determined (a 56-year-old with a history of hypertension and chronic back pain being treated with opioid medication died 37 days after dose 1 and a 70-year-old with a history of cardiac disease was found dead 57 days after dose 2). One vaccine recipient died of suicide 21 days after dose 1, and a 72-year-old vaccine recipient with a history of Crohn’s disease and short bowel syndrome who was hospitalized for acute kidney failure and thrombocytopenia developed complications resulting in multiorgan failure and death 40 days after dose 2.41
A study published in November 2021 in the New England Journal of Medicine that examined the Phase 3 clinical trials noted that there were 17 deaths in vaccine group and 16 deaths in the placebo group. Additionally, study authors reported that one COVID-19 related death occurred among Moderna vaccine recipients and three COVID-19 related deaths occurred among placebo recipients.42 43
Excess Adverse Events in Moderna Vaccine Clinical Trials
A study published in Vaccine in September 2022 found that participants who received an mRNA COVID-19 were at a higher risk of experiencing a serious adverse reaction. The risk of an adverse reaction was higher than what was initially estimated at the time of the Moderna mRNA COVID-19 vaccine EUA in December 2020. According to the study, there were 15.1 additional events for every 10,000 individuals vaccinated and that 1 in 800 adults who received the Moderna mRNA COVID-19 vaccine experienced a serious adverse event.44
Study authors also found that the risk of trial participants suffering a vaccine adverse event was great than the reduction in COVID-19 related hospitalizations.45
On June 17, 2022, the FDA authorized use of two doses of a 100mcg Moderna COVID-19 mRNA vaccine in adolescents 12 through 17 years of age and two doses of a 50mcg Moderna COVID-19 vaccine in children six through 11 years of age under EUA. According to the FDA, the most common adverse events reported after vaccination during clinical trials included injection site redness, pain, and swelling, fever, chills, headache, nausea, vomiting, muscle and joint pain, fatigue, and swollen lymph nodes in the same arm of the injection.46
Twelve vaccine recipients aged 12 through 17 years of age experienced cardiovascular symptoms (chest pain, shortness of breath, and palpitations). This included a 12-year-old male who was hospitalized with chest pain, shortness of breath and abnormal EKG, three additional cases of shortness of breath, seven reports of syncope, and one report of palpitations. Forty-nine events of hypersensitivity reactions occurred among 46 vaccine recipients, and reported as injection site rash, hypersensitivity, dermatitis, and urticaria. No cases of anaphylaxis were reported. Additional adverse events included appendicitis, depression/suicidal ideation, drug-induced liver injury, and surgical repair of pectus excavatum.47
Adverse events of clinical significance reported among six through 11-year-old children who received the vaccine included epilepsy and seizures, loss of taste and smell, Tourette’s Syndrome, chest pain, shortness of breath, palpitations, musculoskeletal chest pain, vasovagal syncope, upper abdominal pain, suicidal ideation, oppositional defiant disorder, disruptive mood disorder, gastrointestinal disorder, asthma, synovitis, neck pain, epiphyseal fracture, Kawasaki Disease, ileus, and bradycardia.48
On June 17, 2022, the FDA authorized use of two doses of a 25mcg Moderna COVID-19 mRNA vaccine in infants and children ages six months through five years. According to the FDA, the most common adverse events reported after vaccination in clinical trials included redness, swelling, and pain at the injection site, fever and underarm (or groin) tenderness and swelling of lymph nodes in the same arm or leg as the injection. In children aged 37 months through five years, the most common adverse events included headache, muscle ache, joint stiffness, fatigue, chills, nausea and vomiting. Among children ages six through 36 months of age, the most commonly reported side effects also included loss of appetite, irritability and crying, and sleepiness.49
Adverse events of clinical significance reported among children aged two through five-years who received the vaccine included erythema multiforme, seizure, chest pain, food allergy (egg), urticaria, rash, conjunctivitis, anaphylaxis, seizure, dyspnea, mental status change, chest pain, metapneumovirus, rhinovirus infection, adenovirus infection, Epstein-Barr virus infection, viral pneumonia, urinary tract infection, bronchial hyperactivity, and humerus fracture. In children aged six through 23 months, additional adverse events that occurred during clinical trials included a diagnosis of Type 1 diabetes, pyrexia with febrile seizure, metapneumovirus infection, rhinovirus infection, mastoiditis, erythema multiforme, electrolyte imbalance, bronchiolitis, febrile convulsion, adenovirus infection, asthma, croup infection, viral gastroenteritis, and cough with wheezing and urticaria.50
According to the federal vaccine adverse event reporting system (VAERS), as of CDC’s July 7, 2023 release of data there were a total of 533,686 reports submitted to VAERS associated with the experimental Moderna COVID-19 vaccine. Noted within these reports were 77,956 serious events including 10,237 deaths; 15,846 permanent disabilities; 54,750 hospitalizations; 15,959 emergency room visits; and 9,508 life threatening events. Of the deaths reported to VAERS, 645 were noted as senior living administration settings, with over 91 percent of overall reported deaths occurring in persons 65 years of age and older.
Health officials have cautioned that symptoms of adverse reactions following COVID-19 vaccination may overlap with those of COVID-19 illness and be difficult to distinguish. However, symptoms of loss of taste or smell, shortness of breath, cough, rhinorrhea or sore throat are not considered common vaccine reactions, and persons experiencing these symptoms post-vaccination may be positive for SARS-CoV-2 or another infection.51
Since the December 2020 EUA of COVID mRNA vaccines, additional serious adverse events have been identified and associated with use of the products.
COVID-19 mRNA Vaccines and Heart Inflammation
By the spring of 2021, multiple cases of pericarditis (inflammation of the membrane surrounding the heart) and myocarditis (inflammation of the heart muscle) following mRNA vaccination had been reported to health authorities. 52 53 Adolescents and young adult males were noted to be at highest risk, especially after the second dose.54
In data presented during the June 23, 2021 Advisory Committee on Immunization Practices (ACIP) meeting, the CDC reported that in females between the age of 12 and 17 years, after the second dose, the case rate of myocarditis/ pericarditis was 9.1 per million doses administered. In males 12 to 17 years of age, however, the rate after the second vaccine dose was 66.7 per one million doses. Cases among females 18 to 24 years old after the second dose were reported at 5.5 per one million doses, while after dose two, males of the same age range were affected at a rate of 56.3 per one million doses. Most cases of myocarditis/pericarditis resulted in hospitalization, and while most were reported as being resolved, the long-term health outcomes were reported to be unknown.55
A January 2022 study conducted by the CDC and several universities found that the risk of myocarditis after receipt of an mRNA COVID-19 vaccine was 133 times higher than the normal risk of the heart condition in the general population. Most cases occurred among 16-17-year-old males following the second dose, at a rate of one in 9,500. The study also reported that 96 percent of individuals who developed myocarditis required hospitalization for their symptoms. While approximately 87 percent of persons hospitalized for myocarditis reported that symptoms had resolved at time of discharge from the hospital, the long-term effects are not known.56 Additional studies have also associated mRNA vaccines with heart inflammation, with researchers reporting the need for further investigation.57 58 59
A population-based cohort study published in the British Medical Journal in December 2021 found that the Moderna COVID-19 vaccine was four times more likely to cause heart inflammation than the Pfizer vaccine.60 A study published in Nature Medicine in December 2021 reported that men under the age of 40 were more likely to develop myocarditis following Moderna vaccination than following SARS-CoV-2 infection.61
In October 2022, Dr. Joseph Ladapo, the Surgeon General of Florida recommended against the use of mRNA COVID-19 vaccine in males 18 to 39 years of age due to the risk of cardiac related deaths post-vaccination. According to an analysis of vaccinated Florida residents, males 18 to 39 years had an 84 percent increased risk of cardiac related death within 28 days of vaccination.62
The CDC, however, has declined to pause use or make changes to the vaccine recommendations, and they continue to reported the benefits to vaccination outweighed the risk. Additionally, they have stated that persons with a history of myocarditis and pericarditis can still receive an mRNA vaccine and persons who developed pericarditis after the first mRNA vaccine dose can choose to receive the second dose after symptoms resolve. The CDC has also advised that individuals who develop myocarditis after the first dose can consider a second dose of the vaccine under certain circumstances. No data has been provided to support this recommendation.63
Additional COVID-19 mRNA Vaccine Adverse Events
Since the issuance of the COVID-19 mRNA vaccines in December 2020, additional serious adverse events have been reported in the medical literature. These adverse events include shingles64, Graves’ Disease (an autoimmune disorder affecting the thyroid), 65 blood clots, 66 67 68 69stroke, 70 Thrombocytopenia with thrombosis syndrome (TTS), 71 acute myocardial events, 72 kidney disorders,73 erythema multiforme (allergic skin reaction characterized by red, raised, symmetrical areas over the entire body),74 Central Nervous System (CNS) Demyelination, including multiple sclerosis (MS),75 Multisystem Inflammatory Syndrome (MIS), 76 tinnitus,77 78 prion disease (a rare, fatal, transmissible spongiform encephalopathy), 79 organ transplant rejection,80 81 anaphylaxis, 82 83 and death.84 85 86 87 88 89 90
A report published in November 2022 in Clinical Research in Cardiology that reviewed autopsy reports of individuals who died suddenly in Germany concluded that COVID-19 vaccines were likely responsible for the sudden death. The researchers limited the study to individuals who did not have any underlying heart issues and those who died within 20 days of the first or second vaccine dose.91 92
Persons who have pre-existing immunity to SARS-CoV-2 may also be at increased risk of severe reactogenicity following mRNA COVID-19 vaccination.93
Pfizer- BioNTech Bivalent COVID-19 mRNA Vaccine Adverse Events
In January 2023, the FDA and CDC announced that they were investigating a potential link between the Pfizer-BioNTech Bivalent mRNA COVID-19 vaccine and ischemic stroke in persons 65 years and older. The possible safety signal, which was detected in the CDC’s Vaccine Safety Datalink (VSD), found an increase risk of stroke within the first 21 days after vaccination when compared to day 22-42.94
Long-term follow-up of clinical trial participants to monitor for conditions such as cancer and autoimmune diseases will become difficult, if not impossible. In December 2020, Pfizer-BioNTech officials stated that they would begin offering the vaccine to placebo recipients by March 1, 2021, which was several months earlier than what they had originally planned for.95 By mid- January 2021, Moderna had already begun offering the vaccine to some placebo group participants.96
Janssen/Johnson & Johnson COVID-19 Vaccine Trial Data
In late September 2020, Janssen/Johnson & Johnson released results of the Phase 1/2a clinical trial for its Ad26.COV2.S vaccine. This study was a double-blind, randomized, placebo-controlled trial and included 796 participants divided into two groups consisting of 402 healthy adults 18 to 55 years of age in one group and 394 healthy elderly individuals 65 years of age and older in the other.
In this trial, the first group was broken out into cohort 1a and cohort 1b. The second group was cohort 3. Trial participants were administered a single intramuscular injection of Ad26.COV2.S at dose levels of either 5×1010 or 1×1011 viral particles (vp) per dose of vaccine.97 98
Approximately 58 percent of participants in cohorts 1a and 1b experienced a localized adverse event, while 64 percent of them also suffered systemic adverse events. Of the participants in cohort 3, 27 percent of them experienced a localized adverse event, and 36 percent suffered systemic events (e.g. fever, irritability, drowsiness, rash, etc.) Of healthy adults aged 18 to 55 years old in cohorts 1a and 1b, 19 percent came down with fevers, while four percent of the adults aged over 65 years old in cohort 3 developed fevers. 99 100
The fevers reported by participants were considered mild or moderate and resolved within one to two days after vaccination. However, five percent (20 participants) of participants in cohorts 1a and 1b suffered from Grade 3 fevers of over 101.3°F.
A news report on the Janssen/Johnson & Johnson Phase 1/2a trial reported that
“[There were two severe adverse events recorded. One participant had hypotension; however, this effect is not related to vaccination as the participant had a history of hypotension. Another participant with fever was hospitalized as a suspected case of COVID-19; however, the fever resolved within 12 hours.”101
The most common adverse events experienced by trial participants were headaches, muscle pain, fatigue and pain the injection site. 102 103
On September 23, 2020, Janssen/Johnson & Johnson announced the start of its Phase 3 clinical trials. The trial, a randomized, double-blind, placebo-controlled study, would enroll up to 60,000 participants in three continents.104 However, on October 12, 2020, all clinical trials stopped after a participant developed an “unexplained illness.” 105 Sources familiar with the event reported that a male in his 20’s had a stroke after receiving the experimental vaccine.106 Clinical trials in the U.S resumed in late October 2020.107
On February 27, 2021, the FDA issued an EUA for Janssen/Johnson & Johnson’s experimental vaccine for use in persons 18 years of age and older.108
Common side effects reported after vaccine administration with the Janssen COVID-19 in clinical trials included injection site pain, headache, fatigue, myalgia, nausea, fever, injection site redness and swelling.109
According to the Fact Sheet for Healthcare Providers issued by the FDA, serious adverse effects (SAE) were reported in 0.4 percent of vaccine recipients and 0.4 percent of placebo recipients. Reported adverse events that occurred among the vaccinated included five cases of urticaria and an additional case of hypersensitivity that was not considered to be anaphylaxis. One vaccine participant reported severe pain in the injection arm that was not responsive to pain medication and another complained of fever, headache and weakness that resolved within three days.110
The Fact Sheet also reported more cases of thromboembolic events, pulmonary embolism, transverse sinus thrombosis, seizures, and tinnitus occurring in those who received the COVID-19 vaccine than those who received the placebo.111
On April 13, 2021, the FDA and CDC paused use of the vaccine after serious blood clots were reported in women between the ages of 18 and 49.112 By April 23, 2021, 15 cases and 3 deaths had been associated with the rare blood clot disorder, now referred to by health officials as thrombosis with thrombocytopenia syndrome (TTS). All cases were reported in women, with two occurring in women over 50 years of age. The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to resume full use of the vaccine in all persons 18 years of age and older on April 23, 2021, by a vote of 10 to 4 (with one voting member abstaining due to a conflict of interest). Those who voted against the recommendation expressed concern regarding the lack of warning on the risk of TTS in women under 50 years of age.113 114
The FDA updated the Janssen/Johnson & Johnson’s COVID-19 Fact Sheet on April 23, 2021 and acknowledged that:115
“Reports of adverse events following use of the Janssen COVID-19 Vaccine under emergency use authorization suggest an increased risk of thrombosis involving the cerebral venous sinuses and other sites (including but not limited to the large blood vessels of the abdomen and the veins of the lower extremities) combined with thrombocytopenia and with onset of symptoms approximately one to two weeks after vaccination. Most cases of thrombosis with thrombocytopenia reported following the Janssen COVID-19 Vaccine have occurred in females ages 18 through 49 years; some have been fatal. The clinical course of these events shares features with autoimmune heparin-induced thrombocytopenia. In individuals with suspected thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine, the use of heparin may be harmful and alternative treatments may be needed. Consultation with hematology specialists is strongly recommended.”
By May 2021, there had been 28 cases of TTS and 3 deaths confirmed by the CDC to be related to the Johnson & Johnson/Janssen COVID-19 vaccine. Additionally, TTS has been reported in men and in women between 50 and 60, in addition to women between 18 and 49 years.116
Due to the risk of TTS following vaccination, ACIP voted on December 16, 2021 to give a preferential recommendation to mRNA COVID-19 vaccines.117 According to the CDC, the Janssen/Johnson & Johnson COVID-19 vaccine should only be used in cases where a person is unable to or unwilling to receive an mRNA COVID-19 vaccine, or where no other vaccine is available.118 The CDC reports that TTS occurs at a rate of one case per 250,000 doses.119
In early September 2021, the European Medicines Agency reported that its Pharmacovigilance Risk Assessment Committee (PRAC) was investigating a link between the Johnson & Johnson/Janssen COVID-19 vaccine and venous thromboembolism (blood clots in the veins). According to PRAC, in the initial clinical trials of the vaccine, a higher rate of venous thromboembolism was noted in the vaccine group when compared to the placebo group. Additional data collected from two larger clinical trials were expected to be submitted to PRAC in advance of vaccine marketing authorization, to determine whether the condition was linked to vaccination.120 121
On July 13, 2021, the FDA announced revisions to the Fact Sheet for Healthcare Providers administering the Johnson & Johnson/Janssen COVID-19 vaccine and the Fact Sheet for Recipients and Caregivers to include information regarding an increased risk of Guillain-Barré Syndrome (GBS) following vaccination. GBS, a serious neurological disorder where the body’s immune system attacks the peripheral nervous system, can cause muscle weakness, paralysis, and even death. According to the press release, the FDA reported 100 cases of GBS following vaccination, with 95 considered serious and requiring hospitalization, and one death. Government health officials noted that there was insufficient evidence to establish a causal relationship between the Johnson & Johnson/Janssen COVID-19 vaccine and GBS, and reported that “the known and potential benefits clearly outweigh the known and potential risks.”122
According to the CDC, most cases occurred within 2 weeks of vaccination and among men, primarily those aged 50 and older.123
On January 11, 2022, the FDA updated the Johnson & Johnson/Janssen COVID-19 Vaccine Fact Sheet for Health Care Providers Administrating with information regarding the serious risk of Immune Thrombocytopenia (ITP) within 42 days of vaccination. ITP is a blood disorder that can cause excessive bruising and bleeding due to very low levels of platelets.124
In January 2022, the Pharmacovigilance and Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that a reasonable association existed between the Johnson & Johnson/Janssen and AstraZeneca COVID-19 vaccines and transverse myelitis (TM), a rare but serious condition that involves inflammation of the spinal cord. Symptoms of TM include tingling, numbness, pain or loss of pain sensation, limb weakness, and issues with bowel and bladder function. According to PRAC, 38 cases of TM have been reported following adenovirus vector vaccines – 25 following the AstraZeneca COVID-19 vaccine and 13 following the Johnson & Johnson/Janssen vaccine.125
As of the March 10, 2023 data release, vaccine adverse events submitted to VAERS associated with the Johnson & Johnson/Janssen COVID-19 vaccine totaled 97,356, with 16,809 noted as serious. Included in these reports were 2,964 deaths; 3,175 permanent disabilities; 10,737 emergency room visits, and 11,697 hospitalizations.
Novavax COVID-19 Vaccine Clinical Trial Data
Maryland-based Novavax Inc, a biotechnology company which, prior to its COVID-19 vaccine, had never successfully delivered a product to market,126 developed an experimental vaccine using recombinant nanoparticle technology. Referred to as a protein subunit vaccine,127 NVX‑CoV2373 contains Novavax’s patented saponin-based Matrix-M™ adjuvant designed to enhance the immune response and stimulate high levels of neutralizing antibodies.128
Matrix-M1 contains nm (nanometers) of nanoparticles composed of Quillaja saponins, phospholipid and cholesterol. Quillaja saponins are chemical compounds extracted from the soapbox tree and are used as emulsifiers in food additives and beverages.129
Phase 1/2 clinical trials involved 131 participants, with 83 administered the NVX-CoV2373 vaccine containing the Matrix-M1 adjuvant to help stimulate an immune response to produce a strong antibody response.130 Of the remaining trial participants, 25 were given the NVX-CoV2373 vaccine without the Matrix-M1 adjuvant and 23 participants were given a placebo of sterile 0.9 percent normal saline. Participant received two intramuscular injections in the deltoid muscle administered three weeks apart.131
According to the results of the clinical trial, two of the 83 participants (one each in groups D and E) suffered “severe adverse events” (fatigue, headache, and malaise) after the first dose. Two participants—one each in groups A and E—had “reactogenicity events” (malaise, fatigue, and tenderness). Following administration of the second dose, one participant in group D had a “severe local event” (tenderness) and eight participants—one or two in each group—had “severe systemic events.” The most common of these severe systemic events were fatigue and joint pain. One participant in group D developed a fever greater than 100 °F.132
Phase 3 clinical trials of NVX-CoV2373 began in the United Kingdom in late September 2020. This trial, a randomized, placebo-controlled, observer-blinded trial, was expected to enroll up to 10,000 volunteers.133
On March 1, 2021, Novavax released pre-peer reviewed research results on their experimental NVX-CoV2373 vaccine. The Phase 2 component of their Phase 1/2 trial was a randomized placebo-controlled trial to identify dosing regimen for the vaccine.
Vaccine arms of about 250 participants received one or two intramuscular doses at 5-μg or 25-μg or placebo, 21 days apart. Subsequent to randomization, 45 percent of participants were 50 to 84 years of age, and side effects were reported as mild and lasted about three days, with intensification after the second dose with the higher dosage of the vaccine.
The lower dose antibody response was reported as 100 percent for all age groups with neutralizing antibody rates exceeding those present in convalescent sera. The study concluded by stating that the two-dose regimen at the lower dose of 5-μg was suited for young and old alike and was highly protective.134
In June 2022, the FDA’s Vaccine and Related Biologics Products Advisory Committee (VRBPAC) voted to recommend issuing Novavax an EUA for its COVID-19 vaccine for adults. VRBPAC made this recommendation despite the risks of myocarditis and pericarditis associated with the vaccine.135
The FDA issued Novavax an EUA for its COVID-19 vaccine on July 13, 2022,136 which was followed by a recommendation for use by the CDC’s ACIP. Novavax was authorized for use in adults 18 years and older as a two-dose primary series who have not previous received a COVID-19 vaccine.137 In August 2022, the FDA expanded use of the vaccine in persons 12 years of age and older.138
According to the Fact Sheet for Health Care Providers administering Novavax COVID-19 vaccine, the most common side effects reported following vaccination were injection site pain and tenderness, malaise/fatigue, muscle pain, headache, joint pain, nausea/vomiting, injection site redness and swelling, and fever. Serious side effects reported following Novavax COVID-19 vaccine include myocarditis, pericarditis, hypersensitivity reactions, chills, injection site itching and swelling of the lymph nodes.139
Novavax COVID-19 vaccines have also been associated with an increased risk of myocarditis and pericarditis. Additional serious cardiac adverse events reported in vaccine recipients included cardiomyopathy, cardiac failure and congestive heart failure.140 Novavax COVID-19 vaccines have also been linked to cholecystitis (inflammation of the gall bladder, thrombotic and embolic events, and Guillain Barre Syndrome (GBS).141
n the fall of 2022, the FDA issued EUAs to both Pfizer-BioNTech and Moderna for bivalent booster dose of COVID-19 mRNA vaccine, containing the original Wuhan strain and the BA.4 and BA.5 SARS-CoV-2 Omicron variant for use in all individuals six months of age and older. Clinical trials of the vaccine were not required by the FDA and no safety data is available to support the use of these experimental products. 142 143 144 145
As of the July 7, 2023 data release, vaccine adverse events submitted to VAERS associated with the Johnson & Johnson/Janssen COVID-19 vaccine totaled 97,799 with 17,186 noted as serious. Included in these reports were 2,806 deaths; 3,320 permanent disabilities; 10,861 emergency room visits, and 12,040 hospitalizations.
On Mar. 10, 2020, the Secretary of Health and Human Services (HHS) invoked the 2005 Public Readiness and Emergency Preparedness (PREP) Act, after declaring that the COVID-19 pandemic was a public health emergency. As a result, manufacturers of COVID-19 vaccines that have been developed to respond to the SARS-CoV-2 pandemic are considered public health emergency “countermeasures”. The PREP Act shields manufacturers and vaccine providers from liability and vaccine injury compensation claims will be processed by the Countermeasures Injury Compensation Program (CICP).146 147 148
All COVID-19 vaccines, including the licensed Pfizer mRNA COVID-19 vaccine, are considered countermeasures. Persons harmed or who die as a result of vaccination may file for benefits through the CICP within one year of injury or death of a loved one.149
As of March 1, 2023, HRSA reports that 8,067 claims alleging injury or death following COVID-19 vaccines have been filed with the CICP. Additionally, 3,185 claims alleging injury or death following additional COVID-19 countermeasures (i.e. medications, treatments, testing) have also been filled. Of the 630 claims where HRSA has rendered a decision, only 21 claims were found to be eligible for compensation and were pending a determination of benefits. HRSA has denied 609 claims, with 210 denied for missing the one year filing deadline, 47 denied for non-receipt of medical records, 251 denied due to product considered ineligible for CICP benefits or due to non-specified reasons, and 101 claims denied due to the “standard of proof not met and/or covered injury not sustained.”150
IMPORTANT NOTE: NVIC encourages you to become fully informed about covid-19 and the covid-19 vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
References:
1 U.S. Food and Drug Administration. Emergency Use Authorization. Mar. 17, 2023.
2 Herper M. Covid-19 vaccine from Pfizer and BioNTech shows positive results. STAT News July 1, 2020.
3 Herper M. Covid-19 vaccine from Pfizer and BioNTech shows positive results. STAT News July 1, 2020.
4 Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Nature August 2020; pp. 589-593.
5 Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Nature August 2020; pp. 589-593.
6 Herper M. Covid-19 vaccine from Pfizer and BioNTech shows positive results. STAT News July 1, 2020.
7 Sagonowsky E. Pfizer sees 'mostly mild to moderate' safety profile in phase 3 COVID-19 vaccine study. Fierce Pharma Sept. 16, 2020.
8 Sagonowsky E. Pfizer sees 'mostly mild to moderate' safety profile in phase 3 COVID-19 vaccine study. Fierce Pharma Sept. 16, 2020.
9 U.S. Food and Drug Administration FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Dec. 11, 2020.
10 U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine - 12 years of age and older, purple cap (must dilute). Dec. 22, 2022.
11 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA. Dec. 10, 2020.
12 Fraiman J. Erviti J, Jones M. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine Sept. 22, 2022; 40 (40): 5798-5805.
13 Fraiman J. Erviti J, Jones M. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine Sept. 22, 2022; 40 (40): 5798-5805.
14 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. May 10, 2021.
15 Soucheray S. CDC advisers green-light COVID vaccine in young teens. CIDRAP News May 12, 2021.
16 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. May 10, 2021.
17 U.S. Food and Drug Administration. Pfizer-BioNTech Fact Sheet for Healthcare Providers for 12 years of age and older, purple cap (must dilute). Nov. 22, 2022.
18 Wallace M. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine. U.S. Centers for Disease Control and Prevention May 12, 2021.
19 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Briefing Document- FDA. Oct. 26, 2021.
20 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Briefing Document- FDA. Oct. 26, 2021.
21 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Briefing Document- FDA. Oct. 26, 2021.
22 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Briefing Document- FDA. Oct. 26, 2021.
23 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Briefing Document- FDA. Oct. 26, 2021.
24 Lee M. Reports of Rare Vulvar Ulcers in Adolescent Girls Following Pfizer COVID-19 Injections. The Epoch Times Apr. 14, 2022.
25 U.S. Food and Drug Admistration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age. June 17, 2022.
26 U.S. Food and Drug Administration. Briefing Document on EUA amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 6 months through 4 years of age. VRBPAC Meeting June 15, 2022.
27 U.S. Food and Drug Administration. Briefing Document on EUA amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 6 months through 4 years of age. VRBPAC Meeting June 15, 2022.
28 Kessler DA, the Working Group, Natanblut S, et al. A New Approach to Reporting Medication and Device Adverse Effects and Product Problems. JAMA 1993;269(21):2765-2768.
29 U.S. Food and Drug Administration.gov. Kessler DA. Introducing MEDWatch: A New Approach to Reporting Medication and Device Adverse Effects and Product Problems. Reprint from JAMA June 9, 1993.
30 Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995; 85: pp. 1706-9.
31 AHRQ Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS). Dec 1, 2007-Sep. 30, 2010
32 Cáceres M. Healthy Clinical Trial Subjects Suffer Grade 3 Side Effects to Moderna’s mRNA COVID-19 Vaccine. The Vaccine Reaction May 24, 2020.
33 Cáceres M. Healthy Clinical Trial Subjects Suffer Grade 3 Side Effects to Moderna’s mRNA COVID-19 Vaccine. The Vaccine Reaction May 24, 2020.
34 Cáceres M. Healthy Clinical Trial Subjects Suffer Grade 3 Side Effects to Moderna’s mRNA COVID-19 Vaccine. The Vaccine Reaction May 24, 2020.
35 National Institutes of Health. Phase 3 clinical trial of investigational vaccine for COVID-19 begins. July 27, 2020.
36 TVR Staff. Moderna’s COVID-19 Vaccine Provokes ‘COVID-Like Symptoms’ in Phase 3 Trial. The Vaccine Reaction Oct. 19, 2020.
37 TVR Staff. Moderna’s COVID-19 Vaccine Provokes ‘COVID-Like Symptoms’ in Phase 3 Trial. The Vaccine Reaction Oct. 19, 2020.
38 Dall C. Early data show Moderna's COVID vaccine 94.5% effective. CIDRAP News Nov. 16, 2020.
39 U.S Food and Drug Administration. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. Dec. 18, 2020.
40 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document - FDA. Dec. 17, 2020.
41 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document - FDA. Dec. 17, 2020.
42 El Sahly HM, Baden LR, Essink B et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. Nov 4, 2021;385(19):1774-1785.
43 El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774-85.
44 Fraiman J. Erviti J, Jones M. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine Sept. 22, 2022; 40 (40): 5798-5805.
45 Fraiman J. Erviti J, Jones M. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine Sept. 22, 2022; 40 (40): 5798-5805.
46 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age. June 17, 2022.
47 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- COVID19 Moderna Vaccine For Use in Pediatrics. VRBPAC Meeting June 14-15, 2022.
48 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- COVID19 Moderna Vaccine For Use in Pediatrics. VRBPAC Meeting June 14-15, 2022.
49 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- COVID19 Moderna Vaccine For Use in Pediatrics. VRBPAC Meeting June 14-15, 2022.
50 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Briefing Document- FDA- COVID19 Moderna Vaccine For Use in Pediatrics. VRBPAC Meeting June 14-15, 2022.
51 U.S. Centers for Disease Control and Prevention. Post Vaccine Considerations for Residents. In: COVID-19. Mar. 13, 2021.
52 European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021. May. 7, 2021.
53 U.S. Centers for Disease Control and Prevention. COVID-19 VaST Work Group Report – May 17, 2021. In: Advisory Committee on Immunization Practices (ACIP). May. 17, 2021.
54 U.S. Centers for Disease Control and Prevention. COVID-19 VaST Work Group Technical Report – May 17, 2021. In: Advisory Committee on Immunization Practices (ACIP). May 20, 2021.
55 Shimabukuro T. COVID-19 Vaccine safety updates. U.S. Centers for Disease Control and Prevention June 23, 2021.
56 Cáceres M. Myocarditis Risk Following mRNA COVID Shots May Be Far Higher Than Previously Estimated. The Vaccine Reaction Jan. 30, 2022.
57 Kim HW, Jenista ER, Wendell DC. et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. Oct 1, 2021;6(10):1196-1201.
58 Montgomery J, Ryan M, Engler R. et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. Oct 1, 2021;6(10):1202-1206.
59 Krug A, Stevenson J, Høeg TB. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis. Eur J Clin Invest. May 2022; 52(5):e13759.
60 Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ Dec 16, 2021;375:e068665.
61 Patone M, Mei XW, Handunnetthi L. et al. Risk of Myocarditis, Pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine Dec. 14, 2021.
62 Nguyen Ly M. Florida Surgeon General Recommends Against mRNA COVID-19 Vaccines for Males Aged 18–39. The Epoch Times Oct. 10, 2022.
63 Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion. U.S. Centers for Disease Control and Prevention June 23, 2021.
64 Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford) Apr. 12, 2021; keab345.
65 Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP et al. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid Sep 2021;31(9):1436-1439
66 Lee EJ, Cines DB, Gernsheimer T et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol May 1, 2021;96(5):534-537.
67 European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021. May. 7, 2021.
68 Stieber Z. Authorities Probe Rare Blood Disorder Among Some COVID-19 Vaccine Recipients. The Epoch Times Feb. 11, 2021.
69 Stieber Z. Pfizer’s COVID-19 Vaccine Linked to Blood Clotting: FDA. The Epoch Times Dec. 17, 2022.
70 Fisher BL. Miami Obstetrician Develops Bleeding Disorder, Dies After Getting COVID-19 Vaccine. The Vaccine Reaction Jan. 11, 2021.
71 Hughes S. Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine. Medscape June 28, 2021.
72 Sun CLF Jaffe E. & Levi R. Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave. Sci Rep Apr. 28, 2022; 12, 6978.
73 TVR Staff. Do mRNA COVID Biologics Cause Skin Allergy and Kidney Disorders? The Vaccine Reaction Aug. 15, 2021.
74 TVR Staff. Do mRNA COVID Biologics Cause Skin Allergy and Kidney Disorders? The Vaccine Reaction Aug. 15, 2021.
75 Khayat-Khoei M, Bhattacharyya S, Katz J. et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. Sept. 4, 2021: 269, 1093–1106.
76 European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021. Sept. 3, 2021.
77 Blasius M. Unheard Concerns: Thousands blame COVID-19 vaccine for hearing problems. ABC 15 Arizona Sept. 17, 2021.
78 Parrino D, Frosolini A, Gallo C et al. Tinnitus following COVID-19 vaccination: report of three cases. Int J Audiol Jun 2022;61(6):526-529.
79 National Institute of Allergy and Infectious Disease. Prion Disease. Oct. 21, 2019.
80 Fujio K., Sung J., Nakatani S. et al. Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review. J Clin Med Aug. 2, 2022, 11(15), 4500.
81 Alhumaid S, Rabaan AA, Dhama K et al. Solid Organ Rejection following SARS-CoV-2 Vaccination or COVID-19 Infection: A Systematic Review and Meta-Analysis. Vaccines (Basel) Aug 10, 2022;10(8):1289.
82 U.S. Centers for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Jan. 15, 2021; 70(2):46–51.
83 Shimabukuro T. COVID-19 vaccine safety update Advisory Committee on Immunization Practices (ACIP). U.S. Centers for Disease Control and Prevention Jan. 27, 2021.
84 Attkisson S. Deaths of Elderly Who Recovered From COVID-19, but Died After Vaccine, Raise Questions. The Epoch Times Feb. 10, 2021.
85 Cáceres M. Hammerin’ Hank’s COVID-19 Vaccination: A “Double-Edged Sword”? The Vaccine Reaction Jan. 31, 2021.
86 Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ January 2021; Pg. 372.
87 TVR Staff. Two Elderly Men Die Hours After Getting COVID-19 Vaccines in Israel. The Vaccine Reaction Jan. 1, 2021.
88 Penza N. Portuguese health worker, 41, dies two days after getting the Pfizer covid vaccine as her father says he 'wants answers'. DailyMail.com Jan. 11, 2021.
89 TVR Staff. Four Persons Die Days After COVID-19 Vaccinations in Portugal, Switzerland and Norway. The Vaccine Reaction Jan. 11, 2021.
90 Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. – Supplementary Appendix. N Engl J Med 2021;385:1761-73.
91 Jones W. New Autopsy Report Reveals Those Who Died Suddenly Were Likely Killed by the Covid Vaccine. The Brownstone Institute Dec. 7, 2022.
92 Schwab C, Domke LM, Hartmann L, et al. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. Clin Res Cardiol. Nov 27, 2022:1–10.
93 Krammer F, Srivastava K, et al. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine MedRxiv Feb. 1, 2021.
94 TVR Staff. CDC, FDA Find Possible Link Between Pfizer’s Bivalent COVID Shot and Strokes. The Vaccine Reaction Jan. 15, 2023.
95 Herper M. Pfizer and BioNTech speed up timeline for offering Covid-19 vaccine to placebo volunteers. Stat News Jan. 1, 2021.
96 Peres J. Vaccine trial participants who received placebo now hop the line for the real thing from Pfizer, Moderna. Chicago Tribune Jan. 14, 2021.
97 Dutta SS. J&J’s COVID-19 vaccine shows potent immune response in phase 2 human trial. News-Medical.Net Sept. 28, 2020.
98 Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. May 13, 2021;384(19):1824-1835.
99 Dutta SS. J&J’s COVID-19 vaccine shows potent immune response in phase 2 human trial. News-Medical.Net Sept. 28, 2020.
100 Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. May 13, 2021;384(19):1824-1835.
101 Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. May 13, 2021;384(19):1824-1835.
102 Dutta SS. J&J’s COVID-19 vaccine shows potent immune response in phase 2 human trial. News-Medical.Net Sept. 28, 2020.
103 Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. May 13, 2021;384(19):1824-1835.
104 Johnson & Johnson. Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate. Sept. 23, 2020.
105 Wamsley L., Harris R., Romo V. Johnson & Johnson, Eli Lilly Pause COVID-19 Drug Trials. National Public Radio Oct. 13, 2020.
106 Herper M. Covid-19 vaccine trials from AstraZeneca, Johnson & Johnson to restart. Stat News Oct. 23, 2020.
107 Steenhuysen J., O’Donnell C., Chander V. AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same. Reuters Oct. 23, 2020.
108 U.S. Food and Drug Administration. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. Feb. 27, 2021.
109 U.S Food and Drug Administration. Janssen COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Mar. 13, 2023.
110 U.S Food and Drug Administration. Janssen COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Mar. 13, 2023.
111 U.S Food and Drug Administration. Janssen COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. Mar. 13, 2023.
112 Soucheray S. US halts J&J COVID vaccine after reports of blood clots. CIDRAP News Apr. 13, 2021.
113 Soucheray S. ACIP opts to lift pause on Johnson & Johnson vaccine. CIDRAP News Apr. 23, 2021.
114 Lee M. Pause on Johnson & Johnson COVID-19 Vaccine Lifted: CDC Vaccine Advisory Committee. The Epoch Times Apr. 23, 2021.
115 U.S. Food and Drug Administration. Janssen COVID-19 Vaccine - Fact Sheet for Healthcare Providers Administering Vaccine. May 5, 2022.
116 Shimabukuro T. Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. U.S. Centers for Disease Control and Prevention. May 12, 2021.
117 TVR Staff. CDC Opts for mRNA Biologics Over J&J COVID Vaccine Following Nine Blood Clotting Deaths. The Vaccine Reaction Dec. 19, 2021.
118 U.S. Centers for Disease Control and Prevention. Appendix A. Guidance for use of Janssen COVID-19 Vaccine. In: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Mar. 16, 2023.
119 U.S. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. In: COVID-19. Mar. 7, 2023.
120 European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021. Sept. 3, 2021.
121 Phillips J. Reports of Rare Body Inflammation After COVID-19 Vaccinations Being Investigated by EU Watchdog. The Epoch Times Sept. 3, 2021.
122 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: July 13, 2021. July 13, 2021.
123 U.S. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. In: COVID-19. Mar. 7, 2023.
124 U.S. Food and Drug Administration. FDA Roundup: January 11, 2022. Jan. 11, 2022.
125 Nguyen Ly M. Rare Spinal Cord Condition Flagged as Potential Adverse Effect of COVID-19 Vaccines: EU Drug Regulator. The Epoch Times Jan. 15, 2022
126 Carchidi A. Does Novavax Have What It Takes to Win the COVID-19 Vaccine Race? The Motley Fool May 24, 2020.
127 Goldman MC. Novavax Gains Following Promising Covid-19 Vaccine Trials. The Street Sept. 3, 2020.
128 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
129 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
130 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
131 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
132 Cáceres M. Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials. The Vaccine Reaction Sept. 14, 2020.
133 Clinical Trials. Novavax launches Phase III trial of Covid-19 vaccine in UK. Sept. 25, 2020.
134 Formica N, Mallory R, Albert G, et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Med. Oct 1, 2021;18(10):e1003769.
135 TVR Staff. FDA Panel Recommends EUA for Novavax COVID-19 Vaccine. The Vaccine Reaction June 13, 2022.
136 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted. July 13, 2022.
137 U.S. Centers for Disease Control and Prevention. CDC Recommends Novavax’s COVID-19 Vaccine for Adults. In: CDC Newsroom. July 19, 2022.
138 U.S. Food and Drug Administration. FDA Roundup: August 19, 2022. Aug. 19, 2022.
139 U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers Administering Vaccine – Novavax. Oct. 19, 2022.
140 U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers Administering Vaccine – Novavax. Oct. 19, 2022.
141 U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers Administering Vaccine – Novavax. Oct. 19, 2022.
142 Stieber Z. Data for Newly Authorized COVID-19 Boosters Based on Mice, Not Humans. The Epoch News Sept. 1, 2022.
143 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. Aug. 31, 2022.
144 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups. Oct. 12, 2022.
145 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. Dec. 8, 2022.
146 Congressional Research Service. The PREP Act and COVID-19: Limiting Liability for Medical Countermeasures. Apr. 13, 2022.
147 Garde D., Branswell H. 6 burning questions Congress could push Covid-19 vaccine makers to answer today. Stat News July 20, 2020.
148 Fisher BL. Parpia R. 2005 PREP Act and 1986 Act Shield Vaccine Manufacturers from Liability The Vaccine Reaction Aug. 10, 2020.
149 Health Resources & Services Administration (HRSA). Frequently Asked Questions. Apr. 2022.
150 Health Resources & Services Administration. Countermeasures Injury Compensation Program (CICP) Data. Mar. 2023.